PG-110

1. PG-110 has no effect on lean mass in mice.

   “with no significant changes observed in lean mass”

   Animalsin diet-induced obese mice in combination with semaglutidetwo weeks

   PG-110, a Novel Bispecific Antibody Targeting ActRII and Myostatin, Enhances Fat-Specific Weight Loss and Improves Bone Health in Combination with GLP-1 Agonist Therapy

   ADA Scientific Sessions 2025 abstract·13 Jun 2025

1. PG-110 increases hind limb BMD in mice.

   “PG-110 treatment markedly increased hind limb BMD”

   Animalsin diet-induced obese micetwo weeks

   PG-110, a Novel Bispecific Antibody Targeting ActRII and Myostatin, Enhances Fat-Specific Weight Loss and Improves Bone Health in Combination with GLP-1 Agonist Therapy

   ADA Scientific Sessions 2025 abstract·13 Jun 2025

More on Hind limb BMD

1. PG-110 increases fat mass loss in mice.

   “When combined with PG-110, fat mass loss was significantly enhanced”

   Animalsin diet-induced obese mice in combination with semaglutidetwo weeks

   PG-110, a Novel Bispecific Antibody Targeting ActRII and Myostatin, Enhances Fat-Specific Weight Loss and Improves Bone Health in Combination with GLP-1 Agonist Therapy

   ADA Scientific Sessions 2025 abstract·13 Jun 2025